Nothing Special   »   [go: up one dir, main page]

Best Stocks Under $5 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $5.00 (5 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Denison Mines stock logo

1. Denison Mines NYSEAMERICAN:DNN

$1.74 -0.03 (-1.42%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison Mines

Market Capitalization
$1.55 billion
P/E Ratio
-173.50
Consensus Rating
Strong Buy
Consensus Price Target
$3.00 (+72.9% Upside)
Volume
17.93 million shares
Average Volume
37.60 million shares
Mereo BioPharma Group stock logo

2. Mereo BioPharma Group NASDAQ:MREO

$2.88 -0.03 (-0.86%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma Group

Market Capitalization
$446.06 million
Consensus Rating
Buy
Consensus Price Target
$7.83 (+172.5% Upside)
Volume
163,536 shares
Average Volume
1.10 million shares
Today's Range
$2.85
$2.93
enCore Energy stock logo

3. enCore Energy NASDAQ:EU

$2.88 -0.02 (-0.52%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. More about enCore Energy

Market Capitalization
$536.40 million
P/E Ratio
-10.29
Consensus Rating
Buy
Consensus Price Target
$6.50 (+125.3% Upside)
Volume
385,546 shares
Average Volume
1.57 million shares
Achieve Life Sciences stock logo

4. Achieve Life Sciences NASDAQ:ACHV

$3.33 +0.04 (+1.25%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. More about Achieve Life Sciences

Market Capitalization
$115.04 million
P/E Ratio
-2.96
Consensus Rating
Buy
Consensus Price Target
$14.80 (+344.3% Upside)
Volume
68,348 shares
Average Volume
310,790 shares
Quince Therapeutics stock logo

5. Quince Therapeutics NASDAQ:QNCX

$1.40 +0.01 (+0.36%)
As of 11:26 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince Therapeutics

Market Capitalization
$61.82 million
P/E Ratio
-1.13
Consensus Rating
Buy
Consensus Price Target
$9.50 (+576.2% Upside)
Volume
73,628 shares
Average Volume
129,639 shares
Bioceres Crop Solutions stock logo

6. Bioceres Crop Solutions NASDAQ:BIOX

$4.76 -0.02 (-0.31%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. More about Bioceres Crop Solutions

Market Capitalization
$298.75 million
P/E Ratio
238.32
Consensus Rating
Buy
Consensus Price Target
$9.88 (+107.2% Upside)
Volume
301,045 shares
Average Volume
260,821 shares
Solid Biosciences stock logo

7. Solid Biosciences NASDAQ:SLDB

$3.83 +0.30 (+8.50%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. More about Solid Biosciences

Market Capitalization
$153.33 million
P/E Ratio
-1.26
Consensus Rating
Buy
Consensus Price Target
$15.30 (+299.5% Upside)
Volume
328,649 shares
Average Volume
755,075 shares
Cardiol Therapeutics stock logo

8. Cardiol Therapeutics NASDAQ:CRDL

$1.26 -0.04 (-2.69%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol Therapeutics

Market Capitalization
$104.50 million
P/E Ratio
-3.24
Consensus Rating
Buy
Consensus Price Target
$8.40 (+564.0% Upside)
Volume
29,661 shares
Average Volume
243,620 shares
Reviva Pharmaceuticals stock logo

9. Reviva Pharmaceuticals NASDAQ:RVPH

$1.78 -0.09 (-4.55%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva Pharmaceuticals

Market Capitalization
$59.62 million
P/E Ratio
-1.61
Consensus Rating
Buy
Consensus Price Target
$11.40 (+538.7% Upside)
Volume
665,387 shares
Average Volume
2.06 million shares
GeoVax Labs stock logo

10. GeoVax Labs NASDAQ:GOVX

$1.66 -0.07 (-3.76%)
As of 11:13 AM Eastern

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax Labs

Market Capitalization
$15.72 million
Consensus Rating
Buy
Consensus Price Target
$14.20 (+752.9% Upside)
Volume
132,408 shares
Average Volume
598,743 shares
Today's Range
$1.64
$1.73
Aclaris Therapeutics stock logo

11. Aclaris Therapeutics NASDAQ:ACRS

$2.16 -0.01 (-0.23%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris Therapeutics

Market Capitalization
$156.08 million
P/E Ratio
-4.20
Consensus Rating
Buy
Consensus Price Target
$11.00 (+408.1% Upside)
Volume
133,517 shares
Average Volume
842,721 shares
Nkarta stock logo

12. Nkarta NASDAQ:NKTX

$2.08 +0.01 (+0.24%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about Nkarta

Market Capitalization
$146.43 million
P/E Ratio
-1.10
Consensus Rating
Buy
Consensus Price Target
$15.00 (+622.9% Upside)
Volume
84,217 shares
Average Volume
1.05 million shares
Rezolve AI stock logo

13. Rezolve AI NASDAQ:RZLV

$2.91 -0.01 (-0.41%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rezolve Ai Ltd. operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. More about Rezolve AI

Market Capitalization
$501.91 million
Consensus Rating
Buy
Consensus Price Target
$6.40 (+120.1% Upside)
Volume
3.10 million shares
Average Volume
8.53 million shares
Today's Range
$2.88
$3.06
Amprius Technologies stock logo

14. Amprius Technologies NYSE:AMPX

$3.30 -0.06 (-1.64%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amprius Technologies, Inc produces and sells ultra-high energy density lithium-ion batteries for mobility applications. The company offers silicon nanowire anode batteries. More about Amprius Technologies

Market Capitalization
$348.74 million
P/E Ratio
-7.32
Consensus Rating
Buy
Consensus Price Target
$9.29 (+181.8% Upside)
Volume
545,196 shares
Average Volume
3.85 million shares
Immunic stock logo

15. Immunic NASDAQ:IMUX

$0.95 +0.01 (+1.07%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about Immunic

Market Capitalization
$85.31 million
P/E Ratio
-0.77
Consensus Rating
Buy
Consensus Price Target
$12.67 (+1,236.1% Upside)
Volume
163,596 shares
Average Volume
916,829 shares
HIVE Digital Technologies stock logo

16. HIVE Digital Technologies NASDAQ:HIVE

$2.80 +0.05 (+1.64%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital Technologies

Market Capitalization
$415.34 million
P/E Ratio
-20.03
Consensus Rating
Buy
Consensus Price Target
$8.08 (+189.2% Upside)
Volume
3.44 million shares
Average Volume
10.71 million shares
Western Copper & Gold stock logo

17. Western Copper & Gold NYSE:WRN

$1.11 +0.03 (+2.77%)
As of 11:16 AM Eastern

Western Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & Gold

Market Capitalization
$220.19 million
P/E Ratio
-55.50
Consensus Rating
Buy
Consensus Price Target
$4.25 (+282.9% Upside)
Volume
35,548 shares
Average Volume
259,045 shares
Gain Therapeutics stock logo

18. Gain Therapeutics NASDAQ:GANX

$2.49 -0.02 (-0.64%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain Therapeutics

Market Capitalization
$66.06 million
P/E Ratio
-2.26
Consensus Rating
Buy
Consensus Price Target
$7.25 (+190.7% Upside)
Volume
50,856 shares
Average Volume
210,671 shares
FibroBiologics stock logo

19. FibroBiologics NASDAQ:FBLG

$1.43 -0.30 (-17.34%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologics

Market Capitalization
$52.43 million
Consensus Rating
Buy
Consensus Price Target
$13.00 (+809.1% Upside)
Volume
631,759 shares
Average Volume
356,971 shares
Today's Range
$1.41
$1.70
Lucid Diagnostics stock logo

20. Lucid Diagnostics NASDAQ:LUCD

$1.38 +0.05 (+3.76%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid Diagnostics

Market Capitalization
$81.89 million
P/E Ratio
-1.21
Consensus Rating
Buy
Consensus Price Target
$3.63 (+162.7% Upside)
Volume
520,802 shares
Average Volume
409,065 shares
PMV Pharmaceuticals stock logo

21. PMV Pharmaceuticals NASDAQ:PMVP

$1.38 +0.03 (+1.84%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. More about PMV Pharmaceuticals

Market Capitalization
$71.67 million
P/E Ratio
-1.39
Consensus Rating
Buy
Consensus Price Target
$5.50 (+297.1% Upside)
Volume
18,788 shares
Average Volume
138,316 shares
Invivyd stock logo

22. Invivyd NASDAQ:IVVD

$1.36 -0.17 (-10.86%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. More about Invivyd

Market Capitalization
$162.09 million
P/E Ratio
-0.69
Consensus Rating
Buy
Consensus Price Target
$7.89 (+482.1% Upside)
Volume
2.78 million shares
Average Volume
27.58 million shares
Unicycive Therapeutics stock logo

23. Unicycive Therapeutics NASDAQ:UNCY

$0.52 -0.01 (-1.43%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. More about Unicycive Therapeutics

Market Capitalization
$54.39 million
P/E Ratio
-0.54
Consensus Rating
Buy
Consensus Price Target
$5.50 (+949.6% Upside)
Volume
373,152 shares
Average Volume
1.07 million shares
Corvus Pharmaceuticals stock logo

24. Corvus Pharmaceuticals NASDAQ:CRVS

$4.96 -0.09 (-1.69%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. More about Corvus Pharmaceuticals

Market Capitalization
$318.73 million
P/E Ratio
-5.33
Consensus Rating
Buy
Consensus Price Target
$12.38 (+149.7% Upside)
Volume
66,361 shares
Average Volume
482,521 shares
Immatics stock logo

25. Immatics NASDAQ:IMTX

$4.93 -0.14 (-2.68%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. More about Immatics

Market Capitalization
$590.83 million
P/E Ratio
-7.50
Consensus Rating
Buy
Consensus Price Target
$16.67 (+237.8% Upside)
Volume
177,412 shares
Average Volume
1.14 million shares

Web Analytics